Global DNA Testing Market - 2023-2030

Market Overview

The global DNA testing market size was valued at US$ XX million in 2023 and is estimated to reach US$ XX million by 2030, growing at a CAGR of 7.4% during the forecast period (2023-2030).

A DNA test, often known as genetic testing, is a medical examination that can spot changes in human genes, chromosomes, or proteins. These mutations can reveal if a person has a genetic disorder or not. DNA tests can also determine a person's risk of contracting a certain illness or passing along a genetic problem. Testing for DNA is optional. Whether to be tested is complex and personal because there are advantages to testing and drawbacks and risks. A geneticist or genetic counselor can assist by outlining the advantages and disadvantages of the test and by going over its social and emotional implications.

Market Dynamics

The major factors driving the global DNA testing market are the development of new tests and technological breakthroughs, demand for direct-to-consumer DNA testing is expanding. and the growing frequency of genetic and chronic diseases is the primary driver propelling the global market for genetic testing.

The development of new tests and technological breakthroughs is expected to drive the market's growth.

The current acceleration of technical development has opened up a wide range of opportunities for market growth. The increase helps the market for specialist testing kits for specialized treatment sectors and the rapid market expansion of chronic diseases. Governments in several countries have successfully accelerated the global acceptance of genetic testing by putting more emphasis on regulating it and increasing public awareness of it. A high entry barrier for new entrants has been created by the increased R&D funding and the large market presence of major enterprises. Innovation in product design, higher quality standards, and strong distribution alliances are all necessary to keep a competitive edge in the market.

For instance, in July 2022, to bring Apollo's specialized high performing NGS tests, such as hereditary cancer genetic screenings (GCC) and pharmacogenetics screenings (PGx), to the wider clinical market, 1health.io Inc. ("1health"), an industry-leading software company, partners with Apollo Health Group. 1health empowers diagnostic laboratories to expand their testing in both the clinical and the direct-to-consumer markets rapidly and securely.

On November 29, 2022, The University of Pecs (UP) and BGI Genomics decided to open a collaborative lab in Hungary. This is a provision of the cooperation agreement between the University and BGI Group, the parent organization of BGI Genomics.

Expensive cost is expected to hamper the market's growth.

The laboratory equipment needs routine maintenance, which costs a lot of money and is one of the factors limiting market expansion.

COVID-19 Impact Analysis

COVID-19 has also had a detrimental impact on the market. For instance, the global use of lockdowns to follow social segregation to contain COVID-19 after the WHO labeled it a pandemic has negatively impacted the DNA testing market. Genetic counselors are generally unable to meet with patients one-on-one, doctors are often unavailable for counseling, and laboratories cannot do the necessary tests, which is the cause of this. Genetic counselors are not considered healthcare professionals by organizations like the Centres for Medical Services. Therefore they are not exempt from practicing during a lockdown. Additionally, clinics limited in-person genetic counseling to aid in the disease's containment.

However, companies that offer genetic testing, like GeneDx, offer a choice where they give the genetic tests as required by the clinician. Similar to how hospitals and other healthcare facilities use telehealth to offer genetic counseling, clinics are starting to do the same. Additionally, because of its importance, parental testing continues to be the least impacted method of DNA testing.

Consequently, COVID-19 has greatly impacted the market for genetic testing. However, the demand for genetic tests has currently approached pre-pandemic levels globally, and it is anticipated that this need will continue to increase.

Segment Analysis

The oncology segment is expected to grow at the fastest CAGR during the forecast period (2022-2029)

The application segment is the highest market holder in the global DNA Testing market. Genetic testing uses medical tests to check for specific gene variants (changes). Several different genetic tests are being used today, and more are being created. There are numerous applications for genetic testing, but this article will concentrate on how it is used to find gene mutations connected to cancer. Predictive genetic testing is used to look for inherited gene alterations that may increase a person's chance of developing particular types of cancer. People with a history of cancer or a particular pattern of cancer in their family may benefit from genetic counseling and testing.

During the projected period, the primary drivers of the cancer segment are the rising incidence of cancers worldwide and the rising public awareness of preventive diagnostics and individualized medication. The American Cancer Society predicted that in 2021 there would be roughly 1,898,160 new cancer cases and 608,570 cancer deaths in the country. The International Agency for Research on Cancer also predicted that by 2040, there would be 30.2 million additional cases of cancer (IARC). Consequently, it is anticipated that an increase in cancer incidence will considerably contribute to the segment's growth.

Genetic tests help determine whether cancer runs in the family and the risk factors for cancer development in the future for people with a family history of the disease. Additionally, genetic testing is done on individuals who do not react to chemotherapy to determine if tumors resistant to treatment have acquired mutations.

Geographical Analysis

Asia Pacific holds the largest market share in the global DNA testing market.

Asia Pacific dominates the global DNA testing market primarily due to its large population, excellent medical infrastructure, and high-income levels. Due to the rising frequency of chronic and genetic conditions in the region and the rising demand for individualized genetic testing services, Asia Pacific now dominates the global market for genetic testing. The market expansion in the Asia Pacific is predicted to be driven by the rising number of product approvals by governments and subsequent launches, as well as the high concentration of key players engaged in research activities to innovate novel genetic testing products.

In August 2022, the debut of GENEe- TO The GENE, THE CORRECT WAY, a cutting-edge idea for providing Genetic Counselling services to patients, has been eagerly anticipated by Redcliffe Labs. Additionally, customers can use the recently opened, cutting-edge Genetic Lab in India, the country's first of its type. Redcliffe Labs hopes to provide a complete solution ranging from routine pathology at the basic level to clinical and high-end research genomics with the opening of a specialist Genetics Lab.

In May 2020, A new step of their collaboration with Illumina was announced by the Chinese company Burning Rock, a leader in next-generation sequencing (NGS) oncology diagnosis. In accordance with the new contract, Burning Rock will be the first genetic testing business in China to create in vitro diagnostic (IVD) tests using tissue samples and circulating tumor DNA (ctDNA) on Illumina's NextSeq 550Dx Sequencing System. The cooperation expands on a 2015 partnership that enabled the use of the MiSeq Dx Sequencing System for several NGS-based cancer therapy selection solutions.

Competitive Landscape

The DNA testing market is moderately competitive with local and global companies' presence. Natera, Inc, Roche Diagnostics, Abbott Laboratories, Cephide Inc, Gen-probe Inc, Illumina, Inc., Thermo Fisher Scientific, Bio-Rad Laboratories, Hologic Inc, Siemens Healthier and more. The key players are adopting various growth strategies such as product launches, mergers & acquisitions, partnerships, and collaborations, contributing to the market's growth. For instance, in October 2022, Medline announced its multi-year vendor partnership with Hoag Memorial Hospital Presbyterian health system to provide essential medical supplies portfolio to the acute and non-acute care network.

Natera, Inc.

Overview: Cell-free DNA (cfDNA) testing pioneer Natera is committed to oncology, women's health, and organ health. In order to safeguard health and enable earlier and more precise actions that result in longer, healthier lives, the goal is to integrate customized genetic testing and diagnostics into the accepted standard of care.

Product Portfolio:

Panorama: Panorama is a blood-based genetic, prenatal screening test of the pregnant person that screens for common chromosomal conditions that affect a baby's health. Panorama uses SNP-based technology to deliver highly accurate results and unique insights for both singleton and twin pregnancies.

The global DNA testing market report would provide access to approx.: 45+market data table, 40+figures and 200 (approximate) pages.